Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–1 of 1 results
Advanced filters: Author: Monika Baudler Clear advanced filters

  • Results from the phase 2/3 clinical trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease reveal no beneficial effects on cognitive measures despite a significant reduction in amyloid plaques and other key biomarkers in those treated with gantenerumab.

    • Stephen Salloway
    • Martin Farlow
    • Christopher H. van Dyck
    Research
    Nature Medicine
    Volume: 27, P: 1187-1196